Published in Angiogenesis on June 03, 2012
Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler Thromb Vasc Biol (2014) 0.99
Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J Biol Chem (2013) 0.99
Optimized polymeric film-based nitric oxide delivery inhibits bacterial growth in a mouse burn wound model. Acta Biomater (2014) 0.88
Skin electroporation of a plasmid encoding hCAP-18/LL-37 host defense peptide promotes wound healing. Mol Ther (2013) 0.84
Mathematical modeling links Wnt signaling to emergent patterns of metabolism in colon cancer. Mol Syst Biol (2017) 0.82
Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance. Front Immunol (2016) 0.82
Monocarboxylate transporters in the brain and in cancer. Biochim Biophys Acta (2016) 0.79
Three-dimensional printed polymeric system to encapsulate human mesenchymal stem cells differentiated into islet-like insulin-producing aggregates for diabetes treatment. J Tissue Eng (2016) 0.78
Lactate does not activate NF-κB in oxidative tumor cells. Front Pharmacol (2015) 0.78
Application of Electron Paramagnetic Resonance (EPR) Oximetry to Monitor Oxygen in Wounds in Diabetic Models. PLoS One (2015) 0.76
Effects of decreased lactate accumulation after dichloroacetate administration on exercise training-induced mitochondrial adaptations in mouse skeletal muscle. Physiol Rep (2015) 0.76
Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators Inflamm (2016) 0.75
Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. Breast Cancer (Auckl) (2017) 0.75
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 7.52
PLGA-based nanoparticles: an overview of biomedical applications. J Control Release (2012) 4.39
Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell (2007) 3.50
Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut (2012) 3.09
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release (2010) 3.06
Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res (2011) 2.96
Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation (2003) 2.35
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release (2006) 2.05
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm (2012) 1.84
Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. Endocrinology (2004) 1.82
Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release (2009) 1.81
Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res (2004) 1.71
Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res (2005) 1.65
Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res (2006) 1.62
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release (2008) 1.59
Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release (2012) 1.58
Glucocorticoids modulate tumor radiation response through a decrease in tumor oxygen consumption. Clin Cancer Res (2007) 1.57
Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des (2012) 1.56
Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One (2012) 1.53
The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res (2006) 1.50
Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev (2004) 1.48
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release (2009) 1.47
An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci (2007) 1.43
Innate immunity and angiogenesis. Circ Res (2005) 1.42
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am J Physiol Endocrinol Metab (2009) 1.38
Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol (2007) 1.35
Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech (2011) 1.35
Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res (2003) 1.32
Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation (2005) 1.30
Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res (2007) 1.27
In vivo methods for the assessment of topical drug bioavailability. Pharm Res (2007) 1.26
Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells. PLoS One (2012) 1.23
Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res (2011) 1.20
Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity. Int J Technol Assess Health Care (2008) 1.19
Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J Pharm Sci (2005) 1.16
Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer (2006) 1.16
Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys (2005) 1.15
Comparison of methods for measuring oxygen consumption in tumor cells in vitro. Anal Biochem (2009) 1.13
PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release (2007) 1.13
Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett (2006) 1.11
Caveolin-1 is critical for the maturation of tumor blood vessels through the regulation of both endothelial tube formation and mural cell recruitment. Am J Pathol (2007) 1.11
The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors. NMR Biomed (2006) 1.09
Both host and graft vessels contribute to revascularization of xenografted human ovarian tissue in a murine model. Fertil Steril (2009) 1.09
The double regulation of endothelial nitric oxide synthase by caveolae and caveolin: a paradox solved through the study of angiogenesis. Trends Cardiovasc Med (2005) 1.08
Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. PLoS One (2013) 1.07
Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat (2007) 1.07
NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc Natl Acad Sci U S A (2010) 1.05
Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation (2004) 1.05
Optimisation of intradermal DNA electrotransfer for immunisation. J Control Release (2007) 1.05
Heat shock protein 90 transfection reduces ischemia-reperfusion-induced myocardial dysfunction via reciprocal endothelial NO synthase serine 1177 phosphorylation and threonine 495 dephosphorylation. Arterioscler Thromb Vasc Biol (2004) 1.05
Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS One (2012) 1.04
Fluconazole distribution in rat dermis following intravenous and topical application: a microdialysis study. J Pharm Sci (2005) 1.04
Bone marrow microenvironment and tumor progression. Cancer Microenviron (2008) 1.04
Caveolin plays a central role in endothelial progenitor cell mobilization and homing in SDF-1-driven postischemic vasculogenesis. Circ Res (2006) 1.04
RhoA activation and interaction with Caveolin-1 are critical for pressure-induced myogenic tone in rat mesenteric resistance arteries. Cardiovasc Res (2006) 1.04
New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol Ther (2011) 1.04
Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J (2002) 1.03
Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med (2002) 1.01
Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res (2003) 1.01
Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery. Physiology (Bethesda) (2007) 0.99
Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis. Cardiovasc Res (2008) 0.99
Role of Activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab (2015) 0.98
Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm (2012) 0.97
Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells--new insights for anti-tumor treatments. FEBS J (2008) 0.96
3D systems delivering VEGF to promote angiogenesis for tissue engineering. J Control Release (2010) 0.96
Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med (2009) 0.96
Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat Res (2009) 0.96
Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol (2012) 0.96
Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release (2004) 0.96
IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA. Am J Physiol Endocrinol Metab (2006) 0.95
Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res (2005) 0.95
Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res (2006) 0.95
Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res (2011) 0.95
Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol (2008) 0.94
Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. Arterioscler Thromb Vasc Biol (2011) 0.94
Nitric oxide delivery to cancer: why and how? Eur J Cancer (2009) 0.93
Impairment of liver GH receptor signaling by fasting. Endocrinology (2002) 0.93
Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am J Physiol Endocrinol Metab (2002) 0.93
pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. J Gene Med (2010) 0.93
Mapping of oxygen by imaging lipids relaxation enhancement: a potential sensitive endogenous MRI contrast to map variations in tissue oxygenation. Magn Reson Med (2012) 0.93
Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab (2002) 0.93
Hollow microneedle arrays for intradermal drug delivery and DNA electroporation. J Membr Biol (2010) 0.92
Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res (2002) 0.92
Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res (2004) 0.92
Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release (2013) 0.92
Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res (2006) 0.92